Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 4.72 USD 7.03%
Market Cap: 213.7m USD

EV/EBITDA
Enterprise Value to EBITDA

-5
Current
-4.9
Median
4.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-5
=
Enterprise Value
153.3m USD
/
EBITDA
-30.4m USD
EBITDA Growth EV/EBITDA to Growth
US
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Average EV/EBITDA: 15.3
Negative Multiple: -5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.7
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.2 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -701.5 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-3
2-Years Forward
EV/EBITDA
-3.3
3-Years Forward
EV/EBITDA
-4.7

See Also

Summary
YMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
YMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YMAB stock valuation using valuation multiples.
Wall Street Estimates
YMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.